BG98523A - Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b - Google Patents

Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b

Info

Publication number
BG98523A
BG98523A BG98523A BG9852394A BG98523A BG 98523 A BG98523 A BG 98523A BG 98523 A BG98523 A BG 98523A BG 9852394 A BG9852394 A BG 9852394A BG 98523 A BG98523 A BG 98523A
Authority
BG
Bulgaria
Prior art keywords
virus
hepatite
ctl
hla
lymphocytic
Prior art date
Application number
BG98523A
Other languages
Bulgarian (bg)
English (en)
Inventor
Maria Vitiello
Robert Chesnut
Original Assignee
Cytel Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corporation filed Critical Cytel Corporation
Publication of BG98523A publication Critical patent/BG98523A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BG98523A 1991-08-26 1994-02-22 Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b BG98523A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US82768292A 1992-01-29 1992-01-29
US87449192A 1992-04-27 1992-04-27
PCT/US1992/007218 WO1993003764A1 (fr) 1991-08-26 1992-08-26 Epitopes de ltc contre le virus de l'hepatite b avec restriction hla

Publications (1)

Publication Number Publication Date
BG98523A true BG98523A (en) 1995-05-31

Family

ID=27419385

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98523A BG98523A (en) 1991-08-26 1994-02-22 Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b

Country Status (16)

Country Link
EP (2) EP0534615B1 (fr)
JP (2) JP3738395B2 (fr)
AU (1) AU687725B2 (fr)
BG (1) BG98523A (fr)
CA (1) CA2115839C (fr)
CZ (1) CZ42794A3 (fr)
DE (1) DE69231621T2 (fr)
ES (1) ES2155060T3 (fr)
FI (1) FI940918A (fr)
GR (1) GR3035575T3 (fr)
HU (1) HUT68510A (fr)
IL (1) IL102964A0 (fr)
NO (1) NO940660L (fr)
NZ (2) NZ270605A (fr)
OA (1) OA09888A (fr)
WO (1) WO1993003764A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
NZ255683A (en) * 1992-08-07 1996-08-27 Cytel Corp Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
DK0708656T3 (da) * 1993-04-27 2002-12-02 United Biomedical Inc Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
WO1995007707A1 (fr) 1993-09-14 1995-03-23 Cytel Corporation Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
AU736032B2 (en) * 1996-12-30 2001-07-26 Innogenetics N.V. Annexin V-binding polypeptides derived from HBsAg and their uses
IL132310A0 (en) * 1997-04-11 2001-03-19 Sangstat Medical Corp Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
ES2400567T3 (es) * 2004-04-21 2013-04-10 The University Of Chicago Inhibidores de cinasa de la cadena ligera de miosina y su uso
US7943140B2 (en) * 2006-08-14 2011-05-17 Thymon, Llc Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
CN102850434B (zh) 2006-10-17 2016-04-13 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP5971945B2 (ja) * 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質の鏡像異性体による免疫応答の刺激
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
MX350220B (es) 2011-08-12 2017-08-30 Oncotherapy Science Inc Peptidos de mphosph1 y vacunas que incluyen los mismos.
US10258676B2 (en) * 2011-09-06 2019-04-16 Agency For Science, Technology And Research Polypeptide vaccine
WO2014047533A1 (fr) 2012-09-21 2014-03-27 Frank Bedu-Addo Compositions de vaccins perfectionnées et méthodes d'utilisation
CN103961697A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
US20140220056A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
SG11201800895VA (en) 2015-08-12 2018-03-28 Oncotherapy Science Inc Depdc1-derived peptide and vaccine containing same
AU2016319075B2 (en) * 2015-09-08 2022-09-22 Universität Zürich Compositions against cat allergy
MX2018004305A (es) 2015-10-08 2018-05-01 Oncotherapy Science Inc Peptido derivado de mphosph1 y vacuna que lo incluye.
WO2017083820A1 (fr) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipides en tant que vecteurs synthétiques pour améliorer le traitement et la présentation de l'antigène ex-vivo en thérapie cellulaire dendritique
WO2018069316A2 (fr) 2016-10-10 2018-04-19 Transgene Sa Polythérapie à base d'un produit immunothérapeutique et de modulateurs de mdsc

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
EP0420913B1 (fr) * 1988-06-14 1995-11-15 Cell Med, Inc. Reactifs immunologiques cellulaires heterofonctionnels, vaccins les contenant et leurs modes d'utilisation
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
EP0510054A1 (fr) * 1990-01-05 1992-10-28 United Biomedical, Inc. Fragments de la proteine du noyau de vih-1

Also Published As

Publication number Publication date
FI940918A0 (fi) 1994-02-25
DE69231621T2 (de) 2001-05-31
EP1018344A2 (fr) 2000-07-12
OA09888A (en) 1994-09-15
DE69231621D1 (de) 2001-02-08
AU2548792A (en) 1993-03-16
JPH06510051A (ja) 1994-11-10
JP3738395B2 (ja) 2006-01-25
AU687725B2 (en) 1998-03-05
IL102964A0 (en) 1993-01-31
EP1018344A3 (fr) 2000-09-20
CA2115839C (fr) 2010-06-01
JP2004075693A (ja) 2004-03-11
JP3586278B2 (ja) 2004-11-10
EP0534615A3 (en) 1994-05-25
NZ270605A (en) 1997-07-27
NZ244103A (en) 1997-07-27
CZ42794A3 (en) 1994-11-16
FI940918A (fi) 1994-04-08
NO940660D0 (no) 1994-02-25
CA2115839A1 (fr) 1993-03-04
GR3035575T3 (en) 2001-06-29
NO940660L (no) 1994-04-22
ES2155060T3 (es) 2001-05-01
EP0534615A2 (fr) 1993-03-31
WO1993003764A1 (fr) 1993-03-04
HU9400581D0 (en) 1994-05-30
HUT68510A (en) 1995-06-28
EP0534615B1 (fr) 2001-01-03

Similar Documents

Publication Publication Date Title
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
PT1294893E (pt) Modificacao do antigenio nuclear de hepatite b
RU94042722A (ru) Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина
DK0610250T4 (da) Vaccine med porcint reproduktivt respiratorisk syndrom (PRRS) og diagnose heraf
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
WO2006041866A3 (fr) Prevention et traitement d'une infection vhc faisant appel a des anticorps diriges contre des epitopes conformationnels et lineaires
DE69327587D1 (de) Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend
ATE97815T1 (de) Kombiniertes hepatitis a- und b-vakzin mit adjuvans.
ATE496630T1 (de) Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
Dezfuli et al. Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
Deresinski Concurrent Plasmodium vivax malaria and dengue
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
WO2002057314A3 (fr) Prevention et traitement d'une infection par le virus de l'hepatite c au moyen d'anticorps diriges contre des epitopes conformationnels
WO2004005316A3 (fr) Prevention et traitement d'une infection de vch faisant appel a des anticorps diriges contre des epitopes conformationnels et lineaires
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
ATE185073T1 (de) Impfstoff zubereitungen
Pütz et al. The rationale of a peptide-conjugate vaccine against measles
Karl et al. Antibodies produced by rabbits immunized with visna virus
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
McLaren et al. Immunity to influenza in ferrets: XII. Immunization of ferrets with TNBP-split influenza virus vaccine
Inchauspe Protection and defence mechanisms in HCV infection